You are here
Home 🌿 Medical Cannabis News 🌿 Australian Study Examining Quality Of Life For Medical Cannabis Patients 🌿News Categories
Australian Study Examining Quality Of Life For Medical Cannabis Patients

Researchers at the University of Sydney are conducting a wide-ranging study concerning quality of life issues for medicinal cannabis patients.
Funded by Australian medicinal cannabis firm Little Green Pharma (LGP), the QUality of life Evaluation STudy (The QUEST Initiative) will delve into related patient outcomes and aims to recruit 2,100 patients by June this year.
The Australian Government is backing the study.
“The QUEST Initiative represents a significant Australian contribution to the global need for reliable, objective and clinically-relevant quality of life data for patients accessing medicinal cannabis treatments for a broad range of chronic conditions,” said Federal Minister for Health, Greg Hunt.
The research, being led by Associate Professor Claudia Rutherford, also has the endorsement of various national bodies including MS Research Australia, Chronic Pain Australia, Arthritis Australia and Epilepsy Action Australia.
“What makes our study unique is the comprehensive suite of patient-reported outcomes – or PROs – being assessed in patients prescribed medicinal cannabis,” said Ass. Prof. Rutherford.
Patients eligible to join the study include those with conditions such as chronic pain, cancer pain, neuropathic pain, insomnia, anxiety, multiple sclerosis and epilepsy who have been prescribed medical cannabis products. It’s envisioned the study will close in March 2022 and may expand to include patients outside Australia.
Information to be collected and analysed will include patient mobility, functionality, pain or discomfort, anxiety and depression, medication requirements and ongoing health costs. Patient outcomes will be tracked over a period of one year.
At this point, there’s not much further information on participating in the study, so those interested should probably contact the University’s Sydney Quality of Life Office.
The mission of the Sydney Quality of Life Office is to achieve the best possible evidence and optimise the use of patient-reported outcomes in clinical trials and routine care.
The University of Sydney is also home to the Lambert Initiative for Cannabinoid Therapeutics, which is engaged in important cannabis research. For example, last year a study led by the Initiative determined consumption of cannabidiol (CBD) doesn’t impair driving ability. It also recently conducted the Cannabis As Medicine Survey (CAMS) 2020 survey.
420 Intel is Your Source for Marijuana News
420 Intel is the leading source for cannabis news from around the world. Get the latest updates on cannabis legalization, politics and technology, as well as developments in medical and recreational marijuana news. Our commitment is to bring you the most important cannabis news stories every day of the week.
At 420 Intel we understand that effective marijuana industry news coverage is a constant endeavor. Every day stories develop regarding cannabis legalization, technological developments, and the medicinal benefits of marijuana use. Each new development carries the potential to impact the marijuana industry regionally, nationally, and internationally. 420 Intel is the marijuana industry news outlet that will keep you up to date on these developments and how they impact the world around you.
With the marijuana industry constantly evolving, you need a cannabis news outlet to keep you abreast of the pertinent information. At 420 Intel, we cover marijuana legalization news throughout the world, offer reliable information for cannabis business owners, detail technological advances that impact the marijuana industry, cover marijuana rallies from across the globe, and everything in between.
You can get 420 Intel news delivered directly to your inbox by signing up for our daily marijuana news, ensuring you’re always kept up to date on the ever-changing cannabis industry. To stay even better informed about marijuana legalization news follow us on Twitter, Facebook and LinkedIn.